Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Nipro Pharma Told to Improve Biz over Violations Spanning 42 Products, Faked Records
February 27, 2023
-
REGULATORY Japan Approves Precedex for Pediatric Use, Expands Labels for Nubeqa, Rinvoq, and More
February 27, 2023
-
REGULATORY Nipro Pharma Likely to Face Business Improvement Order over Violations
February 24, 2023
-
BUSINESS Kidswell Bio Revs Up Biosimilar Push, G-Lasta, Eylea Follow-Ons in Development
February 22, 2023
-
REGULATORY Japan Eyes Two COVID Shots a Year for Elderly, High-Risk People
February 22, 2023
-
ORGANIZATION Policy Veterans’ Group Floats Proposal to Prevent Unprofitability to Stabilize Drug Supply
February 21, 2023
-
BUSINESS Shareholders OK Nichi-Iko’s Delisting, Turnaround under New Management; President to Exit March 8
February 20, 2023
-
BUSINESS ViiV Eyes More Uptake for Japan’s 1st Long-Acting HIV Med, Revs Up Development Drive
February 17, 2023
-
REGULATORY Chuikyo OKs Pricing Plan for Xocova Listing, 100 Billion Yen Threshold for Possible Re-Pricing
February 16, 2023
-
REGULATORY Expert Panel Agrees on Need for Generic Industry Shakeup, Company Criteria Floated
February 16, 2023
-
BUSINESS As Global Race Heats Up for RAS Drugs, Japan Players Joining Fray with New Modalities
February 15, 2023
-
BUSINESS BMS Mulls CAR-T Manufacturing in Japan, Definitive Plans Expected by Year-End
February 14, 2023
-
BUSINESS Asahi Kasei to Push Teribone Auto-Injector, but AG Remains an Option: President
February 13, 2023
-
REGULATORY Japan Cancels 140 Million-Plus Dose Order of Novavax’s COVID Vaccine
February 13, 2023
-
REGULATORY Expert Panel’s Proposal Likely to Involve “2-Stage” Reform, Touch on Funding Too: Chairman
February 10, 2023
-
BUSINESS Kyowa Kirin Has No Plans to Launch Biosame of G-Lasta: President
February 10, 2023
-
REGULATORY Chuikyo Talks Over Sales Criteria to Trigger Possible Xocova Re-Pricing; Is 3-Month-Based Estimate an Overestimate?
February 9, 2023
-
BUSINESS CSL Behring Soon to Launch Home Delivery Service for Hemophilia Therapies
February 8, 2023
-
BUSINESS Next Astellas CEO Says Weathering Xtandi Cliff Is His Biggest Mission
February 7, 2023
-
REGULATORY Expert Panel Member Sakamaki Wants Pricing Overhaul to Push Generic Industry Consolidation
February 6, 2023
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…